Neuroendocrine cell hyperplasia of infancy

Summary

Neuroendocrine cell hyperplasia of infancy (MONDO:0016322) is a disease and 1 clinical trial. A subtype of hyperplasia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide)
• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	neuroendocrine cell hyperplasia of infancy
Mondo ID	MONDO:0016322
Orphanet	217560
ICD-10-CM	J84.841
ICD-11	1641999159
NCIT	C120169
SNOMED CT	707435002
UMLS	C3161105
MedGen	837309
GARD	0020517
Is cancer (heuristic)	no

Also known as: chronic tachypnoe of infancy · CTI · NCHI · NEHI

Disease family

This is a subtype of hyperplasia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › hyperplasia › neuroendocrine cell hyperplasia of infancy

Related subtypes (13): adrenal medullary hyperplasia, atypical endometrial hyperplasia, atypical lobular breast hyperplasia, C-cell hyperplasia, columnar cell hyperplasia of the breast, complex endometrial hyperplasia, endometrial hyperplasia without atypia, parathyroid hyperplasia, simple endometrial hyperplasia, usual ductal breast hyperplasia, focal epithelial hyperplasia, benign prostatic hyperplasia, urothelial hyperplasia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06471556	PHASE2	RECRUITING	Efficacy of Methylprednisolone Pulses in Neuroendocrine Celles Hyperplasia of Infancy : An Early Phase Study